EUnetHTA Joint Action 3 WP4: Cefiderocol for the treatment of infections due to aerobic Gram-negative bacteria in adult patients with limited treatment options

Source:
EUnetHTA
Publisher:
EUnetHTA
Publication date:
16 June 2020

Abstract

This is the pharmaceutical Joint Assessment PTJA11 – Cefiderocol for the treatment of infections due to aerobic Gram-negative bacteria in adult patients with limited treatment options. In April 2020, the European Commission granted marketing authorisation for Fetcroja® (cefiderocol) for the treatment of infections due to aerobic Gram-negative bacteria in adult patients with limited treatment options. This Joint Assessment aims to compare the clinical effectiveness and safety of cefiderocol in the target patient populations with relevant comparators according to the national requirements of EUnetHTA partners.